{"id":"W2131164186","doi":"10.1200/jco.2008.21.2951","title":"Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lapatinib; Medicine; Metastatic breast cancer; Paclitaxel; Human Epidermal Growth Factor Receptor 2; Oncology; Cancer; Internal medicine; Breast cancer; Epidermal growth factor receptor; Trastuzumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005105279,0.0004505146,0.001599303,0.000507965,0.001109403,0.001944731,0.001604657,0.02149442,0.004172457],"category_scores_gemma":[0.02477494,0.0004253113,0.001257335,0.0009914038,0.001021317,0.001543476,0.0005565539,0.01086501,0.002333049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003661337,"about_ca_system_score_gemma":0.002814545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002621526,"about_ca_topic_score_gemma":0.00986738,"domain_scores_codex":[0.9964851,0.001694093,0.0006065119,0.0002905818,0.00063954,0.0002840912],"domain_scores_gemma":[0.9850684,0.00986429,0.001504165,0.0002965027,0.00146712,0.001799554],"domain_codex":null,"domain_gemma":"evaluation","domain_candidate":"evaluation","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006484465,0.0005364579,0.0257897,0.0004963504,0.000660145,0.01439653,0.0003498041,0.0006818294,0.001634425,0.003840391,0.8360601,0.1090698],"study_design_scores_gemma":[0.01178426,0.00464576,0.03684096,0.001923852,0.002590092,0.02207669,0.001928174,0.006294903,0.004040053,0.01780017,0.889797,0.0002780895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.01026626,0.004909012,0.0002142907,0.970287,0.007711722,0.00003930267,0.0003342795,0.00002712628,0.006210916],"genre_scores_gemma":[0.06116091,0.003612228,0.0008774892,0.8968009,0.03348742,0.00006046597,0.0002965287,0.00003717567,0.00366682],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.9948947,"threshold_uncertainty_score":0.02699959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4959209315726059,"score_gpt":0.6018659244381601,"score_spread":0.1059449928655543,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}